Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: Relevance to selective neuronal vulnerability

Journal of Comparative Neurology

Volumn 502, Issue 5, 2007, Pages 683-700

  Kanaan, Nicholas M ^a   Kordower, Jeffrey H ^a   Collier, Timothy J ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Dopamine neurons; Lysosome system; Parkinson's disease; Primate; Ubiquitin proteasome system

Indexed keywords

LIPOFUSCIN; PROTEASOME; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; LYSOSOME; MALE; MESENCEPHALON; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SUBSTANTIA NIGRA;

AGING; ANALYSIS OF VARIANCE; ANIMALS; CELL COUNT; DOPAMINE; FEMALE; INTRANUCLEAR INCLUSION BODIES; LIPOFUSCIN; MACACA MULATTA; MALE; MESENCEPHALON; NEURONS; TYROSINE 3-MONOOXYGENASE; UBIQUITIN;

EID: 34248383674     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.21333     Document Type: Article

References (84)

1. Andersen AH, Zhang Z, Zhang M, Gash DM, Avison MJ. 1999. Age-associated changes in rhesus CNS composition identified by MRI. Brain Res 829:90-98.
2. Arsenault MY, Parent A, Seguela P, Descarries L. 1988. Distribution and morphological characteristics of dopamine-immunoreactive neurone in the midbrain of the squirrel monkey (Saimiri sciureus). J Comp Neurol 267:489-506.
3. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. 1992. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology 42:460-461.
4. Bahr BA, Bendiske J. 2002. The neuropathogenic contributione of lysosomal dysfunction. J Neurochem 83:481-489.
5. Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. 2004. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J Neuropathol Exp Neurol 63:329-337.
6. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA. 1996. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71-76.
7. Berhow MT, Hiroi N, Kobierski LA, Hyman SE, Nestler EJ. 1996. Influence of cocaine on the JAK-STAT pathway in the mesolimbic dopamine system. J Neurosci 16:8019-8026.
8. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
9. Braak E, Sandmann-Keil D, Rub U, Gai WP, de Vos RA, Steur EN, Arai K, Braak H. 2001. Alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol (Berl) 101:195-201.
10. Braak H, Rub U, Sandmann-Keil D, Gai WP, de Vos RA, Jansen Steur EN, Arai K, Braak E. 2000. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol (Berl) 99:489-495.
11. Brunk UT, Terman A. 2002a. The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis. Eur J Biochem 269:1996-2002.
12. Brunk UT, Terman A. 2002b. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med 33:611-619.
13. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6- tetrahydropyridine. Proc Natl Acad Sci U S A 80:4546-4550.
14. Carrard G, Bulteau AL, Petropoulos I, Friguet B. 2002. Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol 34:1461-1474.
15. Cass WA, Grondin R, Andersen AH, Zhang Z, Hardy PA, Hussey-Andersen LK, Rayens WS, Gerhardt GA, Gash DM. 2006. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeye. Neurobiol Aging.
16. Chen EY, Kallwitz E, Leff SE, Cochran EJ, Mufeon EJ, Kordower JH, Mandel RJ. 2000. Age-related decreases in GTP-cyclohydrolase-I immunoreactive neurons in the monkey and human substantia nigra. J Comp Neurol 426(4):534-48.
17. Chiueh CC, Burns RS, Markey SP, Jacobowitz DM, Kopin IJ. 1985. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci 36(3):213-8.
18. Chu Y, Kordower JH. 2007. Age-aesociated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis 25(1): 134-49.
19. Collier TJ, Sortwell CE, Daley BF. 1999. Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J Neurosci 19:5563-5573.
20. Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, Sortwell CE, Bakay RA, Sladek JR, Jr., Kordower JH. 2007. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. Jan 22; [Epub ahead of print].
21. Damier P, Hirsch EC, Agid Y, Graybiel AM. 1999. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:1437-1448.
22. Dawson TM, Dawson VL. 2003. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822.
23. Dickson DW, Wertkin A, Kress Y, Ksiezak-Reding H, Yen SH. 1990. Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects. Lab Invest 63:87-99.
24. Elsworth JD, Deutch AY, Redmond DE Jr, Sladek JR Jr, Roth RH. 1987. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Life Sci 40:193-202.
25. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, Holden JE, Kordower JH. 1998. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401:253-265.
26. Fearnley JM, Lees AJ. 1991. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:2283-2301.
27. Fujigasaki H, Uchihara T, Takahashi J, Matsushita H, Nakamura A, Koyano S, Iwabuchi K, Hirai S, Mizusawa H. 2001. Preferential recruitment of ataxin-3 independent of expanded polyglutamine: an immunohistochemical study on Marinesco bodies. J Neurol Neurosurg Psychiatry 71:518-520.
28. Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM. 2002. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80:168-177.
29. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521-533.
30. Gibb WR, Lees AJ. 1991. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neuroeurg Psychiatry 54:388-396.
31. Goldman-Rakic PS, Brown RM. 1981. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 6:177-187.
32. Gray DA, Woulfe J. 2005. Lipofuscin and aging: a matter of toxic waste. Sci Aging Knowledge Environ 2005:re1-5.
33. Grondin R, Zhang Z, Gerhardt GA, Gash DM. 2000. Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys. Ann Neurol 48:250-253.
34. Gu M, Owen AD, Toffa SE, Cooper JM, Dexter DT, Jenner P, Marsden CD, Schapira AH. 1998. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 158:24-29.
35. Gundersen HJ. 1988. The nucleator. J Microsc 151:3-21.
36. Gundersen HJ, Jensen EB, Kieu K, Nielsen J. 1999. The efficiency of systematic sampling in stereology - reconsidered. J Microsc 193:199-211.
37. Haltia M. 2003. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol 62:1-13.
38. Hastings TG, Lewis DA, Zigmond MJ. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 93:1956-1961.
39. Hirai S, Morimatsu M, Muramatsu A, Eto F, Yoshikawa M. 1977. [Aging of the substantia nigra, with special reference to Marinesco body]. Nippon Ronen Igakkai Zasshi 14:6-13.
40. Hornykiewicz O. 1989. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease - a critical analysis of the neurochemical evidence. Prog Neuropsychopharmacol Biol Psychiatry 13:319-328.
41. Hornykiewicz O. 1988. Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. Mt Sinai J Med 55(1):11-20.
42. Ingram DK, Chefer S, Matochik J, Moscrip TD, Weed J, Roth GS, London ED, Lane MA. 2001. Aging and caloric restriction in nonhuman primates: behavioral and in vivo brain imaging studies. Ann N Y Acad Sci 928:316-326.
43. Irwin I, DeLanney LE, McNeill T, Chan P, Forno LS, Murphy GM, Jr., Di Monte DA, Sandy MS, Langston JW. 1994. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 3:251-265.
44. Jenner P. 2003. Oxidative stress in Parkinson's disease. Ann Neurol 53(Suppl 3):S26-S36.
45. Joel D, Weiner I. 2000. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96:451-474.
46. Jolly RD, Shimada A, Dopfmer I, Slack PM, Birtles MJ, Palmer DN. 1989. Ceroid-lipofuscinosis (Batten's disease): pathogenesis and sequential neuropathological changes in the ovine model. Neuropathol Appl Neurobiol 15:371-383.
47. Keller JN, Dimayuga E, Chen Q, Thorpe J, Gee J, Ding Q. 2004. Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int J Biochem Cell Biol 36:2376-2391.
48. Kettner M, Willwohl D, Hubbard GB, Rub U, Dick EJ Jr, Cox AB, Trottier Y, Auburger G, Braak H, Schultz C. 2002. Intranuclear aggregation of nonexpanded ataxin-3 in Marinesco bodies of the nonhuman primate substantia nigra. Exp Neurol 176:117-121.
49. Kish SJ, Shannak K, Hornykiewicz O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318:876-880.
50. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. 1992. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 58:642-648.
51. Kitt CA, Cork LC, Eidelberg F, Joh TH, Price DL. 1986. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey. Neuroscience 17:1089-10103.
52. Kondoh T, Low WC. 1994. Glutamate uptake blockade induces striatal dopamine release in 6-hydroxydopamine rats with intrastriatal grafts: evidence for host modulation of transplanted dopamine neurons. Exp Neurol 127:191-198.
53. Kumada S, Uchihara T, Hayashi M, Nakamura A, Kikuchi E, Mizutani T, Oda M. 2002. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies. J Neuropathol Exp Neurol 61:984-991.
54. Langston JW. 1998. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol 44(3 Suppl 1):S45-S52.
55. Long JM, Mouton PR, Jucker M, Ingram DK. 1999. What counts in brain aging? Design-based stereological analysis of cell number. J Gerontol A Biol Sci Med Sci 54:B407-B417.
56. Lynd-Balta E, Haber SN. 1994a. The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 59:625-640.
57. Lynd-Balta E, Haber SN. 1994b. The organization of midbrain projections to the ventral striatum in the primate. Neuroscience 59:609-623.
58. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. 2000. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123:665-676.
59. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLanney LE, Langston WJ, Janson AM. 2004. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 471:387-395.
60. McNaught KS, Olanow CW. 2006. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 27:530-545.
61. Meredith GE, Totterdell S, Petroske E, Santa CK, Callison RC Jr, Lau YS. 2002. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 956:156-165.
62. Mizuno Y, Ikebe S, Hattori N, Kondo T, Tanaka M, Ozawa T. 1993. Mitochondrial energy crisis in Parkinson's disease. Adv Neurol 60:282-287.
63. Mizuno Y, Hori S, Kakizuka A, Okamoto K. 2003. Vacuole-creating protein in neurodegenerative diseases in humans. Neurosci Lett 343:77-80.
64. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. 1996. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 46:1044-1050.
65. Muller WE, Pedigo NW Jr. 1994. Brain aging: a risk factor of neurodegenerative disorders and a target for therapeutic intervention. Life Sci 55:1975-1976.
66. Oswald MJ, Palmer DN, Kay GW, Shemilt SJ, Rezaie P, Cooper JD. 2005. Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6). Neurobiol Dis 20:49-63.
67. Pakkenberg H, Andersen BB, Burns RS, Pakkenberg B. 1995. A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res 693:201-206.
68. Palmer DN, Oswald MJ, Westlake VJ, Kay GW. 2002. The origin of fluorescence in the neuronal ceroid lipofuscinoses (Batten disease) and neuron cultures from affected sheep for studies of neurodegeneration. Arch Gerontol Geriatr 34:343-357.
69. Schapira AH. 2006. Mitochondrial disease. Lancet 368:70-82.
70. Schneider JS, Yuwiler A, Markham CH. 1987. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res 411:144-150.
71. Siddiqi ZA, Peters A. 1999. The effect of aging on pars compacta of the substantia nigra in rhesus monkey. J Neuropathol Exp Neurol 58:903-920.
72. Siddiqi Z, Kemper TL, Killiany R. 1999. Age-related neuronal loss from the substantia nigra-pars compacta and ventral tegmental area of the rhesus monkey. J Neuropathol Exp Neurol 58:959-971.
73. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95:6469-6473.
74. Stark AK, Pakkenberg B. 2004. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res 318:81-92.
75. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. 2001. Expression of A53T mutant but not wild-type alpha-synuclein in PC 12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21:9549-9560.
76. Tanner CM, Goldman SM. 1996. Epidemiology of Parkinson's disease. Neurol Clin 14:317-335.
77. Terman A, Brunk UT. 2004. Lipofuscin. Int J Biochem Cell Biol 36:1400-1404.
78. Thai DR, Del TK, Braak H. 2004. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004:pe26.
79. Totaro R, Marini C, Pistoia F, Sacco S, Russo T, Carolei A. 2005. Prevalence of Parkinson's disease in the L'Aquila district, central Italy. Acta Neurol Scand 112:24-28.
80. Uchida K, Ishii A, Kaneda N, Toya S, Nagatsu T, Kohsaka S. 1990. Tetrahydrobiopterin-dependent production of L-dopa in NRK fibroblasts transfected with tyrosine hydroxylase cDNA: future use for intracerebral grafting. Neurosci Lett 109:282-286.
81. Ulfig N. 1989. Altered lipofuscin pigmentation in the basal nucleus (Meynert) in Parkinson's disease. Neurosci Res 6:456-462.
82. West MJ, Gundersen HJ. 1990. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296:1-22.
83. Yuen P, Baxter DW. 1963. The morphology of Marinesco bodies (paranucleolar corpuscles) in the melanin-pigmented nuclei of the brain-stem. J Neurol Neurosurg Psychiatry 26:178-183.
84. Zhang Z, Andersen A, Smith C, Grondin R, Gerhardt G, Gash D. 2000. Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. J Gerontol A Biol Sci Med Sci 55:B473-B480.